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STUDIES OF HYPOXEMIC/ 
REOXYGENATION INJURY: 
WITHOUT AORTIC 
CLAMPING 
V. Role of the L-arginine- 
nitric oxide pathway: The 
nitric oxide paradox 
This study tests the hypothesis that nitric oxide, which is endothelial- 
derived relaxing factor, produces reoxygenation i jury via the L-arginine- 
nitric oxide pathway in hypoxemic immature hearts when they are placed 
on cardiopulmonary b pass. Twenty 3-week-old piglets undergoing 2 hours 
of hypoxemia (oxygen tension about 25 mm Hg) on a ventilator were 
reoxygenated by initiating cardiopulmonary b pass (oxygen tension about 
400 mm Hg). Five animals were not treated, whereas the pump circuit was 
primed with the nitric oxide-synthase inhibitor NG-nitro-L-arginine methyl 
ester (L-NAME, 4 mg/kg) in five piglets. L-Arginine, the substrate for nitric 
oxide, was administered in a fivefold excess (20 mg/kg), together with 
L-NAME in five piglets (L-NAME and L-arginine), and given alone in five 
other piglets (L-arginine). Five normoxemic, instrumented piglets served as 
a control group, and five others underwent 30 minutes of cardiopulmonary 
bypass without preceding hypoxemia. Left ventricular contractility was 
determined as end-systolic elastance by pressure-dimension l ops. Myocar- 
dial conjugated ienes were measured as a marker of lipid peroxidation, 
and the antioxidant reserve capacity (malondialdehyde production in tissue 
incubated with t-butylhydroperoxide) was measured. Nitric oxide level was 
determined in coronary sinus plasma as its spontaneous oxidation product, 
nitrite. Cardiopulmonary bypass per se did not alter left ventricular 
contractility, cause lipid peroxidation, or lower antioxidant capacity. 
Reoxygenation without treatment depressed cardiac contractility (end- 
systolic elastance 38% - 12% of control*), raised nitric oxide (127% above 
hypoxemic values), increased conjugated ienes (1.3 _+ 0.2 vs 0.7 _ 0.1, 
control*), and reduced antioxidant reserve capacity (910 +- 59 vs 471 _ 30, 
control*). Inhibition of nitric oxide production by L-NAME improved 
end-systolic elastance to 84% - 12%,** limited conjugated iene elution 
(0.8 -+ 0.1 vs 1.3 - 0.2, no treatment**), and improved antioxidant reserve 
capacity (679 + 69 vs 910 _ 59, no treatment**). Conversely, L-arginine 
counteracted these beneficial effects of L-NAME, because left ventricular 
function recovered only 24% - 6%,* conjugated ienes were 1.2 --. 0.1,* and 
antioxidant reserve capacity was 826 - 70.* L-Arginine alone caused the 
same deleterious biochemical changes as L-NAME/L-arginine and resulted 
in 60% mortality. The close relationship between postbypass left ventricular 
dysfunction (percent end-systolic elastance) and myocardial conjugated 
diene production (r = 0.752) provides in vivo evidence that lipid peroxida- 
tion contributes to myocardial dysfunction after reoxygenation. These 
results suggest he L-arginine-nitrie oxide pathway, which is normally of 
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physiologic benefit by producing endothelial-derived relaxing factor, is involved in 
the pathogenesis of myocardial reoxygenation injury (*p < 0.05 vs control; **p < 
0.05 vs no treatment, analysis of variance). (J TrIORAC CARDIOVASC SURG 1995;110: 
1200-11) 
L ow output syndrome still contributes to periop- erative morbidity and mortality, 1'2 and early ven- 
tricular dysfunction may develop or persist despite 
successful anatomic orrection of cyanotic ongeni- 
tal defects. 3-5 We have shown previously 6'7 that 
"unintended" reoxygenation i jury occurs when hy- 
poxemic myocardium is placed on cardiopulmonary 
bypass (CPB) and may contribute to postbypass 
myocardial dysfunction, This damage may offset he 
immediate benefits of surgical correction. 
It is accepted generally that the highly reactive 
hydroxyl radical ('OH) causes oxidant injury to the 
myocardium, s Nitric oxide (.NO) is a physiologic 
modulator of vascular tone (known as endothelium- 
derived relaxing factor [EDRF]) 9 and limits neutro- 
phil activation and platelet aggregation. 7 The inter- 
action of -NO and superoxide is well established, 9' 10 
but a biochemical byproduct of this reaction has 
only recently been implicated in tissue injury. 11-13 
Beckman and colleagues H have suggested that gen- 
eration of .OH via the Haber-Weiss pathway may be 
limited in vivo and proposed that -NO reacts with 
superoxide anion (02-)  in pathologic states to pro- 
duce peroxynitrite anion (OONO-)  and "OH. Hogg 
and colleagues 14 also demonstrated that simulta- 
neous generation of .NO and 02-  can lead to 
production of .OH. This chemical reaction may be 
viewed as an alternate pathway o f -OH generation 
that causes reoxygenation damage. 
Our preliminary results show that myocardial 
dysfunction occurs after reoxygenation of hypox- 
emic immature hearts on the initiation of CPB and 
that the L-arginine-'NO pathway is partly involved 
in its pathogenesis. 6 The present study provides 
further evidence that in vivo reoxygenation injury of 
hypoxemic immature heart is mediated in part by 
the .NO pathway and shows that this damage can be 
(1) limited by blocking .NO synthase with an L- 
arginine analog, NG-nitro-L-arginine methyl ester 
(L-NAME), and (2) worsened by increasing .NO 
production by adding L-arginine. 
Material and method 
Thirty immature, 2- to 3-week-old Yorkshire-Duroc 
piglets (3 to 5 kg) were premedicated with 0.5 mg/kg 
diazepam intramuscularly, anesthetized with 30 mg/kg 
pentobarbital intraperitoneally followed by 5 mg/kg intra- 
venously each hour, and supported by a volume-limited 
respirator (Servo 900D, Siemens-Elema, Solna, Sweden) 
via a tracheostomy. All animals received humane care in 
compliance with the "Principles of Laboratory Animal 
Care" formulated by the National Society for Medical 
Research and the "Guide for the Care and Use of 
Laboratory Animals" prepared by the National Academy 
of Sciences and published by the National Institutes of 
Health (NIH Publication No. 86-23, revised 1985). 
The surgical preparation for cardiopulmonary bypass, 
including vessel cannulation for blood sampling and mon- 
itoring, is similar to that described previously] 
Evaluations 
Hemodynamics. Hemodynamic measurements were 
made during control conditions, each 15 minutes during 
hypoxemia, nd 15 and 30 minutes after CPB was discon- 
tinued. Cardiac output was determined by duplicate injec- 
tions of 1 ml of 4 ° C cold saline solution into a central 
Venous catheter. Systemic vascular resistance index 
(SVRI) was calculated after using the following equation: 
SVRI (mm Hg • rain • ml - 1 . kg) 
= (MAP - CVP) (mm Hg) • CO - a (ml/min) • BW (kg) 
where MAP is mean aortic pressure, CVP is central 
venous pressure, and CO is cardiac output in liters per 
minute. 
Left ventricular performance. Left ventricular pressure 
(LV) and ultrasonic rystal signals from sonomicrometer 
crystals placed on the anteroposterior LV epicardial sur- 
face were amplified and digitalized to inscribe LV pres- 
sure-dimension loops. A series of pressure-dimension 
loops under variable loading conditions were generated by 
transient occlusion of the inferior vena cava during a 
7-second period of apnea, during control conditions, and 
30 minutes after discontinuation of CPB. 15 The end- 
systolic pressure volume relationshi p (ESPVR) was ana- 
lyzed by an interactive videographics data analysis com- 
puter program (Spectrum, Bowman Gray School of 
Medicine, Winston-Salem, N.C.) on an 386/33 MHz IBM 
computer (IBM, Armonk, N.Y.), and LV performance 
was described as the slope of linear regression (end- 
systolic elastance [Ees]), as described previously) 6 Post- 
bypass LV contractility was assessed by percent recovery 
of prebypass control value (percent Ees). 
Tissue injury due to oxidants 
Conjugated dienes. Myocardial conjugated dienes 
(CDs) were measured as a marker of lipid peroxidation. 
At the end of each study, LV endocardial biopsy speci- 
mens were frozen immediately and stored in liquid nitro- 
gen, and tissue levels of hydroxy CDs were determined as 
described by Lesnefsky and coworkers. 17
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Antioxidant reserve capacity. In vitro lipid peroxidation 
was measured by the method of Godin and coworkers as to 
assess the antioxidant state or vulnerability to subsequent 
oxidant stress as described previously] 
• NO in coronary sinus blood. Direct measurements of 
• NO cannot be made because of its short half-life. 9'1° 
Thus .NO was determined in plasma as its spontaneous 
oxidation product, nitrite (NO 2 ), which was reconverted 
to .NO and quantitated with a sensitive chemilumines- 
cence assay using a nitrogen oxide analyzer (DASIBI 
Environmental Corp., model 2108, NOx Analyzer, Glen- 
dale, Calif.). The method was modified to increase the 
sensitivity of the detector to 0.8 parts per billion (ppb) of 
• NO (1 pmol/0.1 ml of test sample). Plasma samples were 
obtained from the coronary sinus before hypoxemia, 
immediately before reoxygenation, and 30 minutes after 
reoxygenation. Plasma concentrations taken during CPB 
were adjusted for dilutional effects of the volume in the 
extracorporeal circuit. 
Experimental groups 
Nonhypoxemic studies 
Observation without CPB. Five piglets were anesthe- 
tized , instrumented, and observed over 5 hours while 
breathing inspired oxygen fraction (oxygen tension 
[Fio2] about 0.6 [Po2] about 250 mm Hg) to define the 
stability of an open-chest preparation and provide base- 
line function and biochemical data. 
CPB without hypoxemia or reoxygenation. Five piglets 
underwent 30 minutes of CPB at Po2 about 400 mm Hg 
without preceding hypoxemia, followed by 30 minutes of 
observation with Fio 2 adjusted to keep PO 2 about 100 to 
150 mm Hg after the discontinuation f CPB to determine 
the effects of CPB per se (CPB). 
Hypoxemia and reoxygenation on CPB 
Twenty piglets underwent hypoxemia, which was pro- 
duced by lowering inspired Fio 2 to 6% to 7%, resulting in 
a Po2 of 20 to 30 mm Hg for up to 120 minutes, followed 
by reoxygenation on CPB (Po 2 about 400 mm Hg). 
Reoxygenation before 120 minutes of hypoxemia was 
begun if mean arterial pressure fell below 30 mm Hg. 
Arterial pH was maintained above 7.3 by NaHCO 3 bolus 
intravenous infusions. 
No treatment. Five piglets underwent reoxygenation 
without additives to the prime of the extracorporeal 
circuit. 
L-NAME. In five piglets the CPB prime was supple- 
mented with the L-NAME (4 mg/kg) to block .NO syn- 
thase. 
c-NAME and L-arginine. In five piglets the CPB prime 
was supplemented with L-NAME (4 mg/kg) and a fivefold 
excess of L-arginine (20 mg/kg). 
L-Arginine. In five piglets the CPB prime was supple- 
mented with L-arginine only (20 mg/kg). 
A 30-minute period of reoxygenation on CPB was 
followed by 30 minutes of post-CPB observation with Fio2 
adjusted to keep Po2 about 100 to 150 mm Hg before final 
functional assessments were performed and specimens for 
biochemical analyses were obtained. At the end of each 
experiment, he brain and thoracic and intraabdominal 
organs were inspected visually to confirm closure of the 
foramen ovale and arterial ductus and to determine if
gross evidence of damage occurred. 
Statistics. Data were analyzed with the use of the 
StatView V2.0 program (Abacus Concepts Inc., Berkeley, 
Calif.) on a Macintosh IIci computer (Apple, Inc., Cuper- 
tino, Calif.). Analysis of variance was was used for inter- 
group comparison, and the paired Student  test was used 
for comparison of variables Within experimental groups. 
The relationship between functional impairment (percent 
Ees) and lipid peroxidation (CDs) was tested by linear 
regression analysis. Differences were considered signifi- 
cant at the probability level ofp < 0.05. Group data were 
expressed as mean plus or minus standard error of the 
mean. 
Results 
Hem0dynamic values did not change in nonhy- 
poxemic piglets observed over a 5-hour period with- 
out CLUB. Final hemodynamic and biochemical val- 
ues were unchanged from their baseline levels and 
were similar in piglets undergoing CPB without 
hypoxemia/reoxygenation. 
Hemodynamics. Hypoxemia increased cardiac in- 
dex and stroke work by 39% and 64% initially, 
followed by a gradual decline over an average 
tolerated hypoxemic period of 91 _+ 4 minutes. 
Premature institution of CPB because of hemody- 
namic deterioration was needed in 12 of 20 piglets. 
There was no difference in the mean duration of 
hypoxemia mong the groups. Hypoxemia caused 
systemic vasodilatation i  all groups (Fig. 1), with 
SVRI decreasing further to 66% of prehypoxemic 
values during reoxygenation on CPB after hypox- 
emia in the no treatment and c-arginine groups. The 
aO~lition of L-NAME to the CPB pump circuit raised 
sVRI  to 167% of prehypoxemic values during CPB, 
and this vasoconstriction was reversed by the addi- 
tion of L-arginine to the circuit with L-NAME. CPB 
could be discontinued in only two of five piglets 
treated with L-arginine because of severe hypoten- 
sion that was unresponsive to volume infusion (60% 
mortality). The lowest SVRI after CPB was not6d in 
the two survivors that received L-arginine. 
NO in coronary sinus blood. CPB at Po2 about 
400 mm Hg without preceding hypoxemia raised 
• NO 280% above control values; "NO returned to 
p re-CPB values when CPB was discontinued and 
Po 2 was lowered to 100 to 150 mm Hg (Fig. 2). 
Hypoxemia reduced plasma .NO 20% and reoxygen- 
ation on CPB raised .NO 127% _+ 50% above 
hypoxemic values, but .NO during CPB remained 
substantially lower than without preceding hypox- 
emia (p < 0.01) despite a comparable Po 2 level. 
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Fig. 1. Effects of hypoxemia-reoxygenation nd modification of L-arginine-NO pathway on SVR. No Rx, 
Reoxygenation CPB without reatment; L:NAME, Ag3-nitro-L-arginine methyl ester (4 mg/kg); L-NAME 
and L-arginine, L-NAME (4 mg/kg) and L-arginine (20 mg/kg); L-Arg, L-arginine (20 mg/kg) added to the 
extracorporeal circuit priming fluid. 
The addition of L-NAME to the extracorporeal 
circuit reduced the extent of .NO rise after reoxy- 
genation compared with no treatment (89% _+ 18% 
vs 127% + 15% of hypoxemic values, p < 0.05) (Fig. 
3). Conversely, adding a fivefold excess of L-arginine 
with L-NAME and L-arginine alone augmented -NO 
production markedly during reoxygenation, result- 
ing in values of 204% + 45% and 202% _+ 43% 
above hypoxemic levels, respectively (p < 0.05 vs no 
treatment). 
LV performance. Complete functional recovery 
(Ees = 98% of pre-CPB values) followed CPB 
without preceding hypoxemia. Reoxygenation on 
CPB without altering the pump prime (no treat- 
ment) was associated with profound post-CPB myo- 
cardial dysfunction; Ees recovered only 38% _+ 12% 
of prehypoxemic control values (p < 0.05 vs CPB). 
LV contractility recovered 84% _+ 12% after adding 
L-NAME to the CPB circuit prime (p < 0.05 vs no 
treatment). Conversely, adding a fivefold excess of 
L-arginine counteracted these beneficial effects of 
• NO-synthase inhibition because Ees recovered only 
24% _+ 6%. The most severe post-CPB mechanical 
dysfunction occurred after the use of I.-arginine 
alone; only two of five piglets survived (60% mor- 
tality rate), and Ees recovered only 32% and 19%, 
respectively (Fig, 4). 
Conjugated dienes. LV subendocardial muscle 
CD concentration (Fig. 5) was similar in nonhypox- 
emic piglets placed on CPB to those in normoxemic, 
instrumented piglets (control). Reoxygenation on 
CPB (no treatment) increased myocardial tissue CD 
89% above control values (0.7 -- 0.1 vs 1.3 _+ 0.2, 
p < 0.05). The addition of L-NAME reduced CD 
compared with no treatment (0.8 _+ 0.1 vs 1.3 _+ 0.2, 
p < 0.05), and L-arginine counteracted these bene- 
ficial effects of [.-NAME. Tissue CD values in piglets 
receiving L-arginine alone were comparable with 
those in piglets that were either untreated or re- 
ceived L-NAME and L-arginine. A negative linear 
relationship existed between the degree of myocar- 
dial dysfunction and lipid peroxidation (r = 0.752) 
(Fig. 6). 
Antioxidant reserve capacity. The antioxidant 
state of myocardial tissue was unchanged by CPB 
(Fig. 7). Conversely, reoxygenation while on CPB 
reduced antioxidant reserve capacity, because ma- 
londialdehyde increased signifcantly in myocardial 
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Fig. 2. Coronary sinus .NO during CPB with and without hypoxemia. Data are expressed as percentage of
individual control value in piglets undergoing CPB without hypoxemia (CPB) and reoxygenation without 
treatment (No Rx). 
homogenates incubated with the oxidant -butylhy- 
droperoxide. Reoxygenation-induced r uction in 
antioxidant reserve capacity was limited, by adding 
L-NAME to the extracorporeal circuit. Supplemen- 
tation of the CPB prime with L-arginine alone or in 
combination with L-NAME resulted in a antioxidant 
reserve capacity comparable with untreated piglets. 
Postmortem examination showed pancreatic dam- 
age ranging from petechia to frank hemorrhage in 
all piglets treated with L-NAME alone. No pancre- 
atic alteration occurred in the absence of L-NAME 
or when L-arginine was added. Macroscopic injury 
of other organs did not occur, and the foramen ovale 
and ductus arteriosus were always occluded. 
Discussion 
This study confirms the occurrence of reoxygen- 
ation cardiac dysfunction in the intact immature 
hypoxemic heart. The internal consistency of the 
functional and biochemical findings (NO level, LV 
function, evidence of lipid peroxidation, and re- 
duced antioxidant reserve capacity) provides addi- 
tional evidence that the L-arginine .NO pathway is 
involved in its pathogenesis. We interpret he pro- 
tective effect of a potent .NO synthase inhibitor, 
NG-nitro-L-arginine methyl ester (L-NAME), and 
the deleterious effects of L-arginine, a .NO donor, to 
strengthen our conclusion concerning the role of 
this pathway. These findings are consistent with a 
report by Baccaro and coworkers, 19 which showed 
that L-arginine methylester limits cardiac reoxygen- 
ation injury in the isolated guinea-pig heart model. 
Ventricular dysfunction in cyanotic congenital 
heart disease may develop or persist after successful 
anatomic orrection with CPB (e.g., arterial repair 
of transposition of the great arteries 3'5 and tetralogy 
of Fallot without residual pulmonary stenosis). 4 
Several factors have been implicated: (1) chronic 
exposure to hypoxemia, (2) abnormal loading of the 
ventricle before correction, and (3) injury induced 
by the operative repair itself (i.e., global ischemia). 
Furthermore, experimental studies imply that 
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chronic cyanosis may increase the vulnerability to 
intraoperative ischemia by accelerating depletion of 
high-energy phosphates. 2°'21 Our findings suggest 
that reoxygenation i jury is an additional causative 
factor and implicates the L-arginine-.NO pathway in 
its development. 
Hydroxy CDs are free fatty acid oxidation prod- 
ucts that are possible markers of lipid peroxida- 
tion,17, 22 and studies in isolated heart models doc- 
ument the association of lipid peroxidation and 
myocardial dysfunction 23'24 after reoxygenation. 
Our studies in intact piglets confirm this correlation 
(Fig. 6). Del Nido and colleagues 25reported myo- 
cardial lipid peroxidation, quantified by increased 
production of CDs in preischemic right ventricular 
biopsy samples from cyanotic children placed on 
CPB, suggesting the presence of clinical reoxygen- 
ation myocardial injury. Teoh and colleagues 26re- 
ported recently that myocardial glutathione peroxi- 
dase activity was reduced in patients undergoing 
repair of tetralogy of Fallot, which suggests reduc- 
tion in natural oxygen defense mechanisms. This 
study, together with others, 23' 24 documents reduced 
antioxidant reserve capacity that would increase the 
susceptibility to ischemic damage during aortic 
clamping needed for repair. 
Clinical 27 and experimental 28 studies imply that 
free radicals are involved in the pathogenesis of 
postischemic myocardial dysfunction (stunning), 
and a burst of free radicals has been detected uring 
reperfusion by electron paramagnetic resonance 
spectroscopy and the spin trap o~-phenyl N-tert- 
butylnitrone in a canine model of stunning. 28 Re- 
cently peroxynitrite (ONOO-), a byproduct of the 
interaction of .NO and superoxide anion (02-), has 
been implicated in the pathogenesis of oxidative 
injury. 11-13 Peroxynitrite causes lipid peroxidation by 
at least three mechanisms: (1) hydrogen ion-cata- 
lyzed homolytic leavage to form hydroxyl radical 
and nitrogen dioxide, 11 (2) direct oxidative reaction 
with sulfhydryl groups, 12 and (3) reaction with metal 
ions to form a potent nitrating agent. Our current 
findings suggest hat -NO contributes to reoxygen- 
ation injury possibly through interaction with O 2- to 
form ONOO-, as shown previously by Beckman and 
coworkers 11 and Hogg and colleagues. 14
Our results also provide in vivo proof that -NO 
production is Po 2 dependent..NO was determined 
in plasma as its spontaneous oxidation product, 
nitrite (NO2-), because of its short half-life. 9' 10 The 
biologic reaction (inactivation) of .NO under phys- 
iologic conditions can be accounted for by sponta- 
neous oxidation of .NO to NO2-. Recent studies 
show that 86% of infused .NO is metabolized to 
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nitrite after single passage through the coronary 
system. 9 Coronary sinus .NO was reduced 20% 
during hypoxemia nd increased markedly after 
abrupt reoxygenation on CPB. Endothelial .NO 
production by .NO synthase, a calmodulin-activated 
enzyme, requires reduced nicotinamide adenine 
dinucleotide phosphate and oxygen to oxidize argi- 
nine to -NO and L-citrulline.29 Myocardial .NO 
synthesis thereby becomes reduced during hypox- 
emia, and reoxygenation may stimulate rapid .NO 
synthesis, because intracellular Ca 2+ and other sub- 
strates (arginine and reduced nicotinamide adenine 
dinucleotide phosphate) remain available during 
hypoxemia. 
The .NO values reflect nitrite alone and thereby 
underestimate true -NO production, because these 
studies were performed before the methodology to
measure nitrate and nitrite that yields a .NO level 
that approximates the true value more precisely. 
Our findings documenting the relationship between 
• NO and Po 2 during hypoxemia/reoxygenation are 
consistent with a recent study 3° showing that Vma × 
values for .NO synthase are related irectly to Po 2. 
This raises the possibility of controlling .NO produc- 
tion by modifying how rapidly P02 is raised when 
CPB is initiated. This implies that our use of Po 2 about 
400 mm Hg may have biased results unfavorably and 
that a lower Po 2 strategy may have been more advan- 
tageous. We reported previously that hypoxemia re- 
duces pulmonary .NO production, 31 and perhaps con- 
tributes to hypoxemic pulmonary vasoconstriction. 
The lung is ischemic during CPB so that restoration of
pulmonary blood flow may reflect a form of lung 
reperfusion i jury, which causes endothelial dysfunc- 
tion with consequent inability of the pulmonary endo- 
thelium to generate sutticient .NO to modulate post- 
CPB vascular tone. Consequently, the beneficial 
effects of .NO after CPB may produce an exogenous 
source of .NO to compensate for the limited endothe- 
lial production. 32Therefore, there may be a -NO 
paradox, like the calcium and oxygen paradox, 33 
whereby an important physiologic substance can be 
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Fig. 7. Antioxidant reserve capacity. Vulnerability of hypoxemic and reoxygenated myocardium to 
subsequent oxidant stress is determined by exposing cardiac homogenates to 0 to 4 mmol/L t-butylhy- 
droperoxide (t-BHP) for 30 minutes at 37 ° C (see "text" for description). 
deleterious depending on when and in what concen- 
tration it is administered. 
CPB without preceding hypoxemia (Fig. 2) en- 
hanced • NO production more than reoxygenation 
after hypoxemia, but this overproduction f .NO did 
not cause lipid peroxidation, because antioxidant 
reserve capacity was unaltered by CPB alone. This 
finding is consistent with the observation that CPB is 
safe in the immature heart, as has been shown in the 
adult animal. 22 One explanation for the lesser ise in 
• NO (assessed by NO 2 ) and greater degree of lipid 
peroxidation (at a comparable P02 level) in piglets 
subjected to CPB with preceding hypoxemia may be 
that -NO was inactivated by superoxide anion (0 2 ) 
during the reoxygenation process rather than be- 
coming oxidized to nitrite (NO2-). Consequently, 
the .NO reacts with O2--generated intermediate 
peroxynitrite (OONO) ,  which decomposes homo- 
lytically to -OH and NO212-14 without intermediate 
formation of nitrite 1° and formed this highly toxic 
• OH, which produced the lipid peroxidation quanti- 
fied by the increased CDs. 
L-Arginine, a precursor for .NO, did not increase 
lipid peroxidation despite further enhancement of
• NO generation and its deleterious effects on LV 
function. The extent of oxidant damage was assessed 
by post-CPB biopsy samples of CD content of LV 
subendocardial muscle. We envision reoxygenation 
injury as an ongoing process that is kindled at the 
time molecular 0 2 is reintroduced. Conceivably, the 
severe systemic vasodilatation that precluded dis- 
continuation of CPB in nonsurvivors may have 
compromised assessment of the full extent of oxi- 
dant damage because CPB could be discontinued in
only two of five piglets. L-NAME limited .NO pro- 
duction as SVRI rose substantially during CPB, and 
this was confirmed by the .NO measurements in 
coronary sinus blood. 
Although L-NAME limited cardiac reoxygenation 
injury, .NO synthase inhibition may superimpose 
ischemic damage to other organs because macro- 
scopic evidence of pancreatic damage ranging from 
petechia to hemorrhage occurred in all L-NAME- 
treated piglets. Pancreatic damage is a complication 
of CPB in human subjects, and its pathogenesis 
seems partially related to low regional perfusion. 34 
• NO is a critical modulator of vascular tone so that 
the dose-response r lationship must be performed 
to define the type and concentration of .NO syn- 
thase inhibitor that minimizes oxidant injury and 
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endothelial disruption while maintaining the bene- 
ficial physiologic actions of nitric oxide. The impor- 
tance of in vivo studies is reaffirmed by these 
observations, because the adverse effects of .NO 
inhibition would not be disclosed in in vitro studies. 
Our findings of improved myocardial recovery by 
• NO synthase inhibition in the hypoxemic/reoxygen- 
ation model differ with the recent observations of 
Johnson and colleagues, 3s showing that .NO is car- 
dioprotective in the regional ischemia/reperfusion 
model. Their observations of the benefits of .NO 
donors and precursors in the setting of ischemia/ 
reperfusion have been confirmed. 36-38 They specu- 
late that .NO may be beneficial by inhibiting accu- 
mulation and adherence of circulating blood 
components (i.e., neutrophils and platelets). Blood 
flow is stagnant in regional ischemia, so that neutro- 
phils can adhere to vascular endothelium, plug 
capillaries, become activated during reperfusion, 
and cause myocardial stunning and no reflow phe- 
nomenon on reperfusion. 39 Coronary flow is fixed in 
in vitro studies of hypoxemia in which coronary 
vessels dilate maximally and thereby lower perfusion 
pressure40, 4t and may cause regional hypoperfusion. 
Furthermore, the high coronary flow rate during 
hypoxemia in the in vivo model avoids blood stag- 
nation and may prevent accumulation f lactate that 
may act as a reducing equivalent to limit oxidant 
damage when molecular 0 2 is reintroduced. 42 Fur- 
thermore, our recent study shows that hypoxemic/ 
reoxygenation damage is a more severe insult than 
ischemic/reperfusion stress of comparable duration 
(i.e., 30 minutes), suggesting that a different patho- 
physiology may occur in each process. 43 
Depressed cardiac function related to .NO over- 
production that is reversed by competitive initiation 
of "NO synthesis occurs also in studies of septic 
shock and various cytokines. 44' 45 These observa- 
tions emphasize the importance of the experimental 
model in defining mechanisms of injury and support 
the contention that enhanced .NO generation may 
be either salutary (e.g., ischemia/reperfusion) r 
detrimental depending on clinical or experimental 
conditions. 
We measured antioxidant reserve capacity to as- 
sess the vulnerability to subsequent oxidant stress 
(e.g., exposure to a standard oxidant stimulus) as 
Godin and workers 18 showed this measurement 
reflects the status of endogenous defense mecha- 
nisms (e.g., glutathione). Severe reduction of endo- 
genous antioxidants persisted after reoxygenation 
on CPB, and this is consistent with the recent report 
of Teoh and colleagues, 26 showing reduced glutathi- 
one peroxidase in cyanotic patients placed on extra- 
corporeal circulation. Our findings of postreoxygen- 
ation cardiac dysfunction i  untreated piglets are 
comparable with those isolated heart prepara- 
tions,23, 24 in which hypoxemia depletes endogenous 
antioxidant s ores (i.e., superoxide dismutase, g!uta- 
thione, and thiol groups) and further eduction in 
thiol protein and glutathione follows 0 2 restora- 
tion.23, 24 The rate of restoration of endogenous 
antioxidants can be modified by the energy state 
after reoxygenation, as Tribble and Jones 46 docu- 
mented that reduced nicotinamide adenine dinucle- 
otide phosphate supply from reduced nicotinamide 
adenine dinucleotide via transhydrogenation in mi- 
tochondria is essential for maintaining the reduced 
glutathione pool. The antioxidant reserve capacity 
in L-NAME-treated group, coupled with less lipid 
peroxidation, may thereby reflect the protective 
effects on mitochondrial metabolism. 
The limitations of the acute hypoxemic model are 
acknowledged because chronic cyanosis results in 
myocardial metabolic adaptations 47'48 that are ab- 
sent in the acute preparation. 7 However, the rele- 
vance of the acute model when severe hemodynamic 
deterioration occurred at Po 2 about 25 mm Hg to 
the clinical situation at higher Po2, is shown by the 
similarity of our results to clinical observations in
biopsy findings of cyanotic patients placed on 
CPB.7, 26,49-51 These data lead us to conclude that 
induction of CPB may cause an "unintended" reoxy- 
genation injury resulting in myocardial dysfunction 
and that this can be modified favorably by control- 
ling the method of reoxygenation. Our findings 
imply that the L-arginine-.NO pathway isinvolved in 
the pathogenesis ofmyocardial reoxygenation injury 
of hypoxemic immature piglet heart placed on car- 
diopulmonary b pass. Further studies are needed to 
see if reduced .NO and/or 02- generation will limit 
this damage. 
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